GlassScriptPhysician profile
Alexander Komm
NPI 1245260157
$4,234.45
in general payments reported to CMS, 2019-2025
27 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,679 · 2020: $286 · 2021: $279 · 2022: $360 · 2023: $618 · 2024: $472 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.93 |
| Education | $207.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,706.22 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $500.04 | 2019-2025 | |
| Sk Life Science, INC. | $377.46 | 2020-2025 | |
| Allergan, INC. | $260.78 | 2019-2020 | |
| Ucb, INC. | $139.89 | 2019 | |
| Supernus Pharmaceuticals, INC. | $123.55 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $112.43 | 2019 | |
| Adamas Pharmaceuticals, INC. | $112.05 | 2019 | |
| Neurocrine Biosciences, INC. | $92.12 | 2019 | |
| Avanir Pharmaceuticals, INC. | $90.46 | 2019 | |
| Emd Serono, INC. | $78.98 | 2019 | |
| Amneal Pharmaceuticals LLC | $78.08 | 2019 | |
| Genzyme Corporation | $77.64 | 2019 | |
| Biogen, INC. | $73.29 | 2019 | |
| Eisai INC. | $65.99 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.72 | 2019 | |
| Sunovion Pharmaceuticals INC. | $57.16 | 2019 | |
| Arbor Pharmaceuticals, INC. | $48.22 | 2019 | |
| Lundbeck LLC | $35.25 | 2019 | |
| Acorda Therapeutics, INC | $29.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.48 | 2019 | |
| Lilly USA, LLC | $23.58 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.16 | 2025 | Rexulti |
| Akcea Therapeutics, INC. | $13.72 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.91 | 2019 | |
| Promius Pharma LLC | $10.87 | 2019 | |
| Sumitomo Pharma America, INC. | $4.46 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Komm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.